Application of JAK inhibitors in the treatment of rheumatoid arthritis: a systematic analysis based on clinical trial databases and registries - PubMed
4 hours ago
- #JAK inhibitors
- #clinical trials
- #rheumatoid arthritis
- Systematic analysis of JAK inhibitors for rheumatoid arthritis (RA) from 2014-2025.
- China (42 trials) and the U.S. (32 trials) lead global research on JAK inhibitors.
- Shift from Pan-JAK agents to multi-target combinations like TYK2 + JAK1 observed.
- JAK inhibitors show target-dependent efficacy with infections as common adverse events.
- Serious adverse event (SAE) rates range from 2.91% to 7.37%.
- Future research should focus on Phase IV studies and standardized data disclosure.